TY - JOUR
T1 - Usefulness of Predilation Before Transcatheter Aortic Valve Implantation
AU - Pagnesi, Matteo
AU - Jabbour, Richard J.
AU - Latib, Azeem
AU - Kawamoto, Hiroyoshi
AU - Tanaka, Akihito
AU - Regazzoli, Damiano
AU - Mangieri, Antonio
AU - Montalto, Claudio
AU - Ancona, Marco B.
AU - Giannini, Francesco
AU - Chieffo, Alaide
AU - Montorfano, Matteo
AU - Monaco, Fabrizio
AU - Castiglioni, Alessandro
AU - Alfieri, Ottavio
AU - Colombo, Antonio
PY - 2016/1/21
Y1 - 2016/1/21
N2 - Balloon predilation is historically considered a requirement before performing transcatheter aortic valve implantation (TAVI). As the procedure has evolved, it has been questioned whether it is actually needed, but data are lacking on mid-term outcomes. The aim of this study was to evaluate the effect of balloon predilation before TAVI. A total of 517 patients who underwent transfemoral TAVI from November 2007 to October 2015 were analyzed. The devices implanted included the Medtronic CoreValve (n = 216), Medtronic Evolut R (n = 30), Edwards SAPIEN XT (n = 210), and Edwards SAPIEN 3 (n = 61). Patients were divided into 2 groups depending on whether pre-implantation balloon aortic valvuloplasty (pre-BAV) was performed (n = 326) or not (n = 191). Major adverse cardiac and cerebrovascular events (MACCE) were primarily evaluated. Propensity score matching was used to adjust for differences in baseline characteristics and potential confounders (n = 113 pairs). In the overall cohort, patients without pre-BAV had a significantly higher MACCE rate at 30 days, driven by a higher incidence of stroke (0.3% pre-BAV vs 3.7% no-pre-BAV, p
AB - Balloon predilation is historically considered a requirement before performing transcatheter aortic valve implantation (TAVI). As the procedure has evolved, it has been questioned whether it is actually needed, but data are lacking on mid-term outcomes. The aim of this study was to evaluate the effect of balloon predilation before TAVI. A total of 517 patients who underwent transfemoral TAVI from November 2007 to October 2015 were analyzed. The devices implanted included the Medtronic CoreValve (n = 216), Medtronic Evolut R (n = 30), Edwards SAPIEN XT (n = 210), and Edwards SAPIEN 3 (n = 61). Patients were divided into 2 groups depending on whether pre-implantation balloon aortic valvuloplasty (pre-BAV) was performed (n = 326) or not (n = 191). Major adverse cardiac and cerebrovascular events (MACCE) were primarily evaluated. Propensity score matching was used to adjust for differences in baseline characteristics and potential confounders (n = 113 pairs). In the overall cohort, patients without pre-BAV had a significantly higher MACCE rate at 30 days, driven by a higher incidence of stroke (0.3% pre-BAV vs 3.7% no-pre-BAV, p
UR - http://www.scopus.com/inward/record.url?scp=84966714135&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84966714135&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2016.04.018
DO - 10.1016/j.amjcard.2016.04.018
M3 - Article
AN - SCOPUS:84966714135
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
ER -